Selective use of abciximab in coronary stenting: Overall outcomes can still be equivalent to those in the EPISTENT treatment group

International Journal of Cardiovascular Interventions

Volumn 4, Issue 1, 2001, Pages 15-20

  Price, D J A ^a   Campbell, P G ^a   Sutton, A G C ^a   Grech, E D ^a   Davies, A ^a   Hall, J A ^a   De Belder, M A ^a  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Abciximab; Stent

Indexed keywords

ABCIXIMAB;

ACUTE HEART INFARCTION; ADULT; AGED; ANGINA PECTORIS; ARTICLE; CONTROLLED STUDY; CORONARY STENT; COST CONTROL; FEMALE; HEART MUSCLE ISCHEMIA; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THROMBOSIS; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 0034859117     PISSN: 14628848     EISSN: None     Source Type: Journal    
DOI: 10.1080/146288401316922643     Document Type: Article

References (11)

1. A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents
2. A clinical trial comparing three antithrombotic drug regimens after coronary artery stenting
3. Routine use of abciximab in coronary stenting?
4. The wide use of IIb/IIIa inhibitors in interventional cardiology - Is it justified?
5. The economics of GP IIb/IIIa inhibition in percutaneous coronary intervention
6. Targeting patients undergoing angioplasty for thrombus inhibition
7. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
8. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor inhibitor in high risk coronary angioplasty
9. Guidelines for percutaneous transluminal coronary angioplasty: A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty)
10. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
11. Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis